β受体阻滞剂治疗老年人房颤合并收缩性心力衰竭的疗效及安全性  

Efficacy and Safety ofβ-blockers in the Treatment of Elderly Patients with Atrial Fibrillation Complicated with Systolic Heart Failure

作　　者：李妍[1] LI Yan(No.1 Department of Ward,Jilin Provincial People's Hospital,Changchun 130021,China)

机构地区：[1]吉林省人民医院干疗一科,吉林长春130021

出　　处：《中国医药指南》2020年第9期24-25,共2页Guide of China Medicine

摘　　要：目的探究β受体阻滞剂治疗老年人房颤合并收缩性心力衰竭的疗效及安全性。方法选取2015年9月至2017年8月我院收治的98例老年房颤合并收缩性心理衰竭患者作为研究对象。将所有患者随机均分成实验组、对照组两组,每组各49例。给予对照组患者常规用强心、利尿、扩管药物治疗,给予实验组患者常规治疗基础上的β受体阻滞剂(美托洛尔)治疗。观察、对比两组患者的治疗效果、心功能情况及超声心动图结果。结果经过治疗,实验组患者治疗总有效率为93.88%,对照组患者治疗总有效率为79.59%,实验组患者治疗效果显著高于对照组,P<0.05。治疗前,两组患者LVDD、LVSD、LVEF指标差异不明显,P>0.05。治疗4周后、1年后,两组患者LVDD、LVSD、LVEF指标均显著好于治疗前,P<0.05,差异有统计学意义;且实验组患者LVDD、LVSD、LVEF指标均显著好于对照组,P<0.05,差异有统计学意义。治疗1年后,实验组患者LVEF指标显著好于对照组,P<0.05;治疗1年后实验组患者LVDD、LVSD指标与对照组相比差异不明显,P>0.05。结论采用β受体阻滞剂治疗老年人房颤合并收缩性心力衰竭显著改善了患者治疗效果,提高了患者生存率,安全性、耐受性高,值得临床推广及应用。Objectives To explore the efficacy and safety of β-blockers in the treatment of elderly patients with atrial fibrillation complicated with systolic heart failure.Methods 98 patients with atrial fibrillation complicated with systolic mental failure admitted to our hospital from September 2015 to August 2017 were selected as subjects.All patients were randomly divided into experimental group and control group,with 49 cases in each group.Patients in the control group were routinely treated with cardiotonic,diuretic,and expandable drugs,and patients in the experimental group were treated with conventional betablockers(metoprolol).The therapeutic effects,cardiac function and echocardiographic results of the two groups were observed and compared.Results After treatment,the total effective rate of the experimental group was 93.88%,and the total effective rate of the control group was 79.59%.The therapeutic effect of the experimental group was significantly higher than that of the control group,P<0.05.Before treatment,the differences of LVDD,LVSD and LVEF between the two groups were not significant,P>0.05.After 4 weeks of treatment and 1 year later,the LVDD,LVSD and LVEF indexes of the two groups were significantly better than those before treatment,P<0.05,the difference was statistically significant;and the LVDD,LVSD and LVEF indexes of the experimental group were significantly better than the control group.Group,P<0.05,the difference was statistically significant.After 1 year of treatment,the LVEF index of the experimental group was significantly better than that of the control group,P<0.05.After 1 year of treatment,the LVDD and LVSD indexes of the experimental group were not significantly different from the control group,P>0.05.Conclusion The use ofβ-blockers in the treatment of elderly patients with atrial fibrillation and systolic heart failure significantly improved the patient's treatment effect,improved patient survival,safety,tolerance,and is worthy of clinical promotion and application.

关 键 词：受体阻滞剂 老年人 房颤合并收缩性心力衰竭 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]